MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why RMTI Stock Traded Steady Today — RQD Quant Desk Flash
$7.31 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.30
Rockwell Medical Inc. (RMTI) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $29.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.30 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RMTI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY RMTI SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 41 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$7.89-5.8% Next Q
36
Q2 (-2Q)Grade E$7.43-6.6% Next Q
33
Q3 (-1Q)Grade E$6.94+5.3% Next Q
31
CurrentGrade E$7.31-10% Hist 90D α
28
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RMTI Turnaround Squeeze
While RMTI currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.91) and Max Pain ($7.68) forces dealer call-delta covering toward $13.55.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RMTI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RMTI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RMTI Stock Traded Steady Today — RQD Quant Desk Flash
Rockwell Medical Inc. (RMTI) slipped 0.00% to $7.31, trading at 30% of its 52-week range ($4.89 – $12.9). Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 30% of its 52-week range ($4.89 – $12.9) with RSI-14 at 41 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.31 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 16.9% gross margin and $0 annual free cash flow.
Live RMTI Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RMTI)
- ✓Walkthrough of RMTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RMTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.93%📐 HORIZONTAL RANGE
2026-10-30O $6.94H $7.31L $6.71C $7.31VOL 39.5K
RES: $9.82SUP: $6.68SMA50: $7.91SMA200: $8.24
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RMTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RMTI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RMTI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RMTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RMTI)
Health Care Rank #971 of 1016
⚔️ RNAZ vs RMTI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RMTI vs. RNAZ, NXTC, BCTX, CPHI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Rockwell Medical Inc. (RMTI) ranks #971 by composite RQD confidence (28/100, grade E) and #806 by equity capitalization ($29.5M). Within this direct 5-issuer industry benchmark cohort, RMTI leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with RMTI at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RMTI
ACTIVE
Rockwell Medical Inc. | E | 28/100 | — | 16.9% | -10.6% | 0.00% | $29.5M | Benchmark Subject |
| RNAZ TransCode Therapeutics Inc. | D | 47/100 | — | — | -35.0% | -0.57% | $29.3M | /rnaz-vs-rmti → |
| NXTC NextCure Inc. | D | 48/100 | — | — | -35.0% | +2.92% | $29.9M | /nxtc-vs-rmti → |
| BCTX BriaCell Therapeutics Corp. | D- | 41/100 | — | — | — | -5.43% | $28.9M | /bctx-vs-rmti → |
| CPHI China Pharma Holdings Inc. | D | 45/100 | — | -3.2% | -11.4% | +4.84% | $28.0M | /cphi-vs-rmti → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001041024In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rockwell Medical Inc. (RMTI) reported GAAP revenue of $69.3M (-31.8% vs. FY2024 revenue of $101.5M ) , GAAP net income of -$5.3M, operating cash flow of -$659.0K, and free cash flow of -$659.0K (-115.7% YoY). On the balance sheet, RMTI closed FY2025 with $57.1M in total assets against $8.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $69.3M | -$5.3M | -$659.0K | -$659.0K | $57.1M | $8.8M |
| FY2024 (FY) | 2024-12-31 | $101.5M | -$480.0K | $4.2M | $4.2M | $59.2M | $8.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.4M | -$9.4M | -$9.4M | — | — |
3. RMTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Rockwell Medical Inc. (NASDAQ: RMTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $7.31 (0.00% 1D, market cap $29.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RMTI ranks #971 in composite RQD confidence.
How does RMTI compare to RNAZ and NXTC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RMTI carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 16.9%, and ROIC of -10.6%. By comparison, RNAZ (TransCode Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $29.3M) and NXTC (NextCure Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $29.9M). Among the 5-stock peer group, RMTI leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RMTI?
Per RMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041024), Rockwell Medical Inc. generated $69.3M in revenue (-31.8% YoY), -$5.3M in net income, and -$659.0K in free cash flow against $57.1M in total assets and $8.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RMTI trading relative to its 50-day, 200-day, and 52-week technical levels?
RMTI last traded at $7.31 (0.00% on volume of 4,350 shares), positioning the stock -7.59% below its 50-day simple moving average ($7.91) and -11.29% below its 200-day simple moving average ($8.24). Across its 52-week range of $4.89 to $12.90, RMTI sits at the 30.2% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.40 to $8.22).
RMTI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RMTI stock moving today?
Why RMTI Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.